KRAS Inhibitor Market: By Cancer Type (Breast Cancer, Pancreatic Cancer, Colon Cancer, Lung Cancer, and Others), By Application (Development and Drug Formulation, Development of Molecular Diagnostics, Disease Diagnostics, Drug Discovery and Development, and Others), By End User (Ambulatory Surgical Centers, Academic and Cancer Research Institute, Clinical Laboratories, Contract Research Organizations (CRO), and Others), and Geography

KRAS Inhibitor Market was valued at USD 90.6 million in 2023 and is expected to grow to USD 682.3 million by 2029, growing at a 23.3% CAGR from 2024 to 2030. KRAS also known as Kirsten rat sarcoma virus, is a gene that provides for making a protein called K-RAS. The mutated form has been found in some types of cancer such as lung cancer, breast cancer, and pancreatic cancer, and is responsible due to self-activation capacity when guanosine exchange factor (GEF) protein displaces GDP from the nucleotide-binding site. The KRAS market-driven pancreatic cancer is extremely fatal.

According to the World Health Organization (WHO), Cancer is a leading cause of death worldwide, accounting for nearly 10 million deaths in 2020, or nearly one in six deaths. The most common cancers are breast, lung, colon rectum, and prostate cancers. Rising demand for chemotherapy, radiation therapy, and other therapies accelerated the market, introduction of novel drug development drives the market growth. The diagnostic procedure followed in cancer detection, Bio makers testing which informs therapy options during diseases, and demand for novel drugs and FDA approval as a companion diagnostic application for identification of non-small cell lung cancer may be eligible for treatment with Lumakras creates opportunities in the market. lack of understanding and regarding the benefits of KRAS may limit the expansion in the market which is restraints in the market growth. Geographically, North America held the major market share in 2022 and is expected to dominate the global KRAS inhibitor market in the forecasted years.

KRAS Inhibitor Market Key Developments:

• In December 2022, the FDA Approved Adagrasib for Locally Advanced or Metastatic KRAS G12C+ NSCLC
• In September 2022, Amgen announced detailed results from the global Phase 3 CodeBreaK 200 trial, which showed once-daily oral LUMAKRAS®/LUMYKRAS® (sotorasib) led to significantly superior progression-free survival and a significantly higher objective response rate in patients with KRAS G12C-mutated non-small cell lung cancer (NSCLC)